Thus, the recent novel insights into the oncogenic mechanisms of C/EBPα p30 illustrate how a truncating mutation in a transcription factor can result in a functional isoform that has gained novel molecular functions to enable AML development. This evidence concerns the gene CEBPA and acute myeloid leukemia.